News
New BTK inhibitor shows promise in previously failed B-cell malignancies
Pirtobrutinib (formerly known as LOXO-305) is an oral-dose, highly selective, reversible BTK inhibitor.
News
Prognostic gene signature identifies high- vs. low-risk DLBCL patients
The researchers calculated risk scores using their prognostic gene set in three additional published DLBCL studies.
News
CLL, MBL had lower response rates to flu vaccination, compared with healthy adults
Patients with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis were assessed for their immune response.
News
Ceftolozane-tazobactam found effective in critically ill patients with Pseudomonas aeruginosa infections
The primary outcome of the study was to assess the efficacy and toxicity of C/T therapy.
News
Eliminating hepatitis by 2030: HHS releases new strategic plan
The United States “is currently facing unprecedented hepatitis A outbreaks, while progress in preventing hepatitis B has stalled, and hepatitis C...
News
Eliminating hepatitis by 2030: HHS releases new strategic plan
The United States “is currently facing unprecedented hepatitis A outbreaks, while progress in preventing hepatitis B has stalled, and hepatitis C...
News
Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A
Inhibitors occurred at an early age of 13 years with a prevalence of 2.6%, but were not associated with increased mortality.